{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:15:36Z","timestamp":1791584136421,"version":"4.3.4"},"reference-count":10,"publisher":"S. Karger AG","issue":"8","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>Purpose: Bacille Calmette-Guerin (BCG) is considered the most effective agent for non-muscle invasive bladder cancer (NMIBC). However, due to BCG-related toxicity, multiple studies have suggested the role of newer chemotherapeutic drugs. The aim of our study was to evaluate intravesical gemcitabine + docetaxel (Gem\/Doce) versus BCG with respect to quality of life (QOL), safety, and efficacy in NMIBC. Methods: A total of 60 patients with NMIBC were evaluated between July 2019 and December 2020 in a prospective manner. The sample size calculation was done, keeping in mind the incidence of intravesical BCG-related complications of up to 50\u201360% and 20\u201330% for Gem\/Doce combination. The p value of 0.05 was kept as statistically significant. The enrollment ratio was kept at 1, and power of study was aimed at 80%. The study population was alternatively assigned to two groups (BCG vs. Gem\/Doce) of 30 patients each. Both the groups received 6 weekly doses of induction therapy followed by 6 monthly doses of maintenance therapy if no recurrence was noted at interim follow-up. QOL scores, safety, and efficacy were assessed at beginning of intravesical therapy, end of induction, and 6 months of maintenance therapy. Cystoscopy examination and cytology were performed at the end of induction therapy and 3-monthly thereafter. Result: The preliminary results at the end of 6 months following maintenance therapy showed that the demographic profile, histological stage, and grade were comparable between two groups. The QOL scores using QLQ-30 and QLQ-BLS-24 showed statistically significant differences with the Gem\/Doce arm showing better outcomes. There were no progressions to higher stage, while one recurrence each was seen in both groups. Patient-related side effects measured by CTCAE (Common Terminology Criteria for Adverse Events)version 5 showed that the BCG group had higher toxicity profile as compared to Gem\/Doce group. Conclusion: Gem\/Doce combination intravesical therapy is a promising alternative to BCG for treatment of NMIBC, showing better QOL measures and lesser side effects.<\/jats:p>","DOI":"10.1159\/000524098","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T17:00:36Z","timestamp":1654189236000},"page":"784-790","source":"Crossref","is-referenced-by-count":20,"title":["Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study"],"prefix":"10.1159","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-7348","authenticated-orcid":false,"given":"Tarun","family":"Pareek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpesh","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya Prakash","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10880.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)58737-6"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0302-2838(03)00371-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx661.008"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-150008"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.11.019"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.01.009"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.068"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.7_suppl.469"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.12.057"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/uin\/article-pdf\/106\/8\/784\/3980018\/000524098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/uin\/article-pdf\/106\/8\/784\/3980018\/000524098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:58:05Z","timestamp":1745409485000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000524098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,2]]},"published-print":{"date-parts":[[2022,8,23]]}},"URL":"https:\/\/doi.org\/10.1159\/000524098","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.19958711","asserted-by":"subject"}]},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}